NO332215B1 - Stabiliserte vandige suspensjonsformulering for parenteral administrering, anvendelse av denne samt ampulle inneholdende formuleringen - Google Patents
Stabiliserte vandige suspensjonsformulering for parenteral administrering, anvendelse av denne samt ampulle inneholdende formuleringen Download PDFInfo
- Publication number
- NO332215B1 NO332215B1 NO20025431A NO20025431A NO332215B1 NO 332215 B1 NO332215 B1 NO 332215B1 NO 20025431 A NO20025431 A NO 20025431A NO 20025431 A NO20025431 A NO 20025431A NO 332215 B1 NO332215 B1 NO 332215B1
- Authority
- NO
- Norway
- Prior art keywords
- formulation according
- weight
- volume
- formulation
- methionine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000009472 formulation Methods 0.000 title claims abstract description 98
- 239000007900 aqueous suspension Substances 0.000 title claims abstract description 45
- 238000007911 parenteral administration Methods 0.000 title claims abstract description 19
- 239000003708 ampul Substances 0.000 title claims description 6
- 229960004452 methionine Drugs 0.000 claims abstract description 52
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 51
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229930195722 L-methionine Natural products 0.000 claims abstract description 50
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims abstract description 32
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims abstract description 32
- -1 steroid compound Chemical class 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 claims abstract description 18
- 229960005416 estradiol cypionate Drugs 0.000 claims abstract description 18
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims abstract description 17
- 229960000255 exemestane Drugs 0.000 claims abstract description 16
- 239000000872 buffer Substances 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000008363 phosphate buffer Substances 0.000 claims description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 239000000375 suspending agent Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 239000006172 buffering agent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000003016 phosphoric acids Chemical class 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- XYGMEFJSKQEBTO-KUJXMBTLSA-N Clostebol acetate Chemical compound C1CC2=C(Cl)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 XYGMEFJSKQEBTO-KUJXMBTLSA-N 0.000 claims description 2
- KHKDIUPVDIEHAH-KXLSUQFWSA-N Oxabolone cipionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C(O)=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 KHKDIUPVDIEHAH-KXLSUQFWSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 229960002039 clostebol acetate Drugs 0.000 claims description 2
- 229960001293 methylprednisolone acetate Drugs 0.000 claims description 2
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- HPFVBGJFAYZEBE-ZLQWOROUSA-N testosterone cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)CCC1CCCC1 HPFVBGJFAYZEBE-ZLQWOROUSA-N 0.000 claims description 2
- 229960000921 testosterone cypionate Drugs 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 description 44
- 239000000126 substance Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012928 buffer substance Substances 0.000 description 10
- 230000020477 pH reduction Effects 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- 230000006641 stabilisation Effects 0.000 description 8
- 238000011105 stabilization Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000003139 buffering effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000001627 detrimental effect Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 238000005189 flocculation Methods 0.000 description 5
- 230000016615 flocculation Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 3
- NEDJKVIUOSOCNB-AWPSVMBFSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclo Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21.O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 NEDJKVIUOSOCNB-AWPSVMBFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 150000008040 ionic compounds Chemical class 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 229940078693 1-myristylpicolinium Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ZCTSINFCZHUVLI-UHFFFAOYSA-M 4-methyl-1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(C)C=C1 ZCTSINFCZHUVLI-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000007971 pharmaceutical suspension Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- OMSBSIXAZZRIRW-UHFFFAOYSA-N 2-methylpyridine;hydrochloride Chemical compound Cl.CC1=CC=CC=N1 OMSBSIXAZZRIRW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000817240 Mus musculus Eosinophil cationic protein 1 Proteins 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-N sodium;2-hydroxypropane-2-sulfonic acid Chemical compound [Na+].CC(C)(O)S(O)(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/571,395 US6495534B2 (en) | 2000-05-15 | 2000-05-15 | Stabilized aqueous suspensions for parenteral use |
| PCT/EP2001/004643 WO2001087266A1 (en) | 2000-05-15 | 2001-04-25 | Stabilized aqueous suspensions for parenteral use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20025431D0 NO20025431D0 (no) | 2002-11-13 |
| NO20025431L NO20025431L (no) | 2003-01-13 |
| NO332215B1 true NO332215B1 (no) | 2012-07-30 |
Family
ID=24283530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025431A NO332215B1 (no) | 2000-05-15 | 2002-11-13 | Stabiliserte vandige suspensjonsformulering for parenteral administrering, anvendelse av denne samt ampulle inneholdende formuleringen |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6495534B2 (zh) |
| EP (1) | EP1282402B1 (zh) |
| JP (1) | JP4205341B2 (zh) |
| KR (1) | KR100828957B1 (zh) |
| CN (1) | CN100473376C (zh) |
| AR (3) | AR029924A1 (zh) |
| AT (1) | ATE313316T1 (zh) |
| AU (2) | AU2001267371B2 (zh) |
| BR (1) | BR0110841A (zh) |
| CA (1) | CA2409059C (zh) |
| CZ (1) | CZ303872B6 (zh) |
| DE (1) | DE60116084T2 (zh) |
| DK (1) | DK1282402T3 (zh) |
| EA (1) | EA007682B1 (zh) |
| EE (1) | EE05376B1 (zh) |
| ES (1) | ES2254443T3 (zh) |
| HK (1) | HK1054194B (zh) |
| HU (1) | HU229800B1 (zh) |
| IL (2) | IL152537A (zh) |
| IN (1) | IN224279B (zh) |
| MX (1) | MXPA02011195A (zh) |
| NO (1) | NO332215B1 (zh) |
| NZ (1) | NZ522324A (zh) |
| PE (1) | PE20011322A1 (zh) |
| PL (1) | PL203075B1 (zh) |
| SI (1) | SI1282402T1 (zh) |
| SK (1) | SK287641B6 (zh) |
| TW (1) | TWI256310B (zh) |
| WO (1) | WO2001087266A1 (zh) |
| ZA (1) | ZA200208738B (zh) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| US7387623B2 (en) | 2002-08-21 | 2008-06-17 | Pfizer Inc. | Injectable pharmaceutical suspension in a two-chamber vial |
| AU2003290647A1 (en) * | 2002-11-08 | 2004-06-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using taxane derivatives |
| JP2006522133A (ja) * | 2003-03-31 | 2006-09-28 | アルザ・コーポレーション | 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション |
| SI1660009T1 (sl) * | 2003-09-03 | 2015-07-31 | Miscon Trading S.A. | Metode za zdravljenje endometrioze |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| WO2006031720A2 (en) * | 2004-09-14 | 2006-03-23 | Molecular Therapeutics, Inc. | D-methionine formulation with improved biopharmaceutical properties |
| US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US20070154546A1 (en) * | 2005-12-30 | 2007-07-05 | Zhang Jack Y | Sustained release pharmaceutical compositions |
| WO2007095341A2 (en) * | 2006-02-15 | 2007-08-23 | Tika Läkemedel Ab | Sterilization of corticosteroids with reduced mass loss |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| JP5371180B2 (ja) * | 2006-06-15 | 2013-12-18 | 日立コンシューマエレクトロニクス株式会社 | 投写型映像表示装置 |
| JP5624766B2 (ja) * | 2006-09-27 | 2014-11-12 | イーグル・ファーマシューティカルズ・インコーポレーテッド | アルコールを含まないアルガトロバン製剤 |
| US7687516B2 (en) * | 2006-09-27 | 2010-03-30 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
| US20100076019A1 (en) * | 2006-10-11 | 2010-03-25 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
| GB0625962D0 (en) * | 2006-12-23 | 2007-02-07 | Renovo Ltd | Medicaments and methods for wound healing |
| WO2009026473A2 (en) * | 2007-08-21 | 2009-02-26 | Hollis-Eden Pharmaceuticals, Inc. | Stabilized therapeutic compositions and formulations |
| US8287729B2 (en) * | 2008-04-28 | 2012-10-16 | California Polytechnic Corporation | Field water purification system |
| GB0813628D0 (en) * | 2008-07-25 | 2008-09-03 | Arrow Int Ltd | Stable coated anti-cancer agent |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| EP3150702B1 (en) | 2011-06-19 | 2021-05-19 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| UA74095U (ru) * | 2012-07-20 | 2012-10-10 | Николай Иванович Гуменюк | Препарат для лечения туберкулеза |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CA2924335A1 (en) | 2013-09-17 | 2015-03-26 | Terapio Corporation | Methods of preventing or treating mucositis using rlip76 |
| CN104706578B (zh) * | 2013-12-14 | 2019-04-23 | 天津金耀集团有限公司 | 一种醋酸甲泼尼龙混悬注射液组合物的制备方法 |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US9265396B1 (en) | 2015-03-16 | 2016-02-23 | Irobot Corporation | Autonomous floor cleaning with removable pad |
| US9907449B2 (en) | 2015-03-16 | 2018-03-06 | Irobot Corporation | Autonomous floor cleaning with a removable pad |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017149492A1 (en) * | 2016-03-02 | 2017-09-08 | Teva Pharmaceutical Industries Ltd. | Medroxyprogesterone acetate injectable compositions and methods of use |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11590077B2 (en) * | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| US20190134059A1 (en) * | 2016-05-06 | 2019-05-09 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| WO2019048906A1 (en) * | 2017-09-07 | 2019-03-14 | Teva Pharmaceutical Industries Ltd. | INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE |
| MX2020002606A (es) * | 2017-09-07 | 2020-10-05 | Teva Pharma | Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso. |
| EP3706719A1 (en) * | 2017-11-08 | 2020-09-16 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| JP7482777B2 (ja) * | 2018-01-11 | 2024-05-14 | バイロファーマ バイオロジクス エルエルシー | 安定なコルチコステロイド組成物 |
| BR112021004194A2 (pt) * | 2018-09-07 | 2021-05-25 | Teva Pharmaceutical Industries Ltd | composições injetáveis de acetato de medroxiprogesterona e métodos de uso |
| US10544923B1 (en) | 2018-11-06 | 2020-01-28 | Verifone, Inc. | Devices and methods for optical-based tamper detection using variable light characteristics |
| AU2019384801A1 (en) | 2018-11-20 | 2021-06-10 | Spectrum Solutions, Llc | Sample collection system including sealing cap and valve |
| IT201900002857A1 (it) | 2019-02-27 | 2020-08-27 | Ntc S R L | Procedimento di riempimento di contenitori con una polvere |
| US11701094B2 (en) | 2019-06-20 | 2023-07-18 | Spectrum Solutions L.L.C. | Sample collection system including valve and plug assemblies |
| KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| WO2022245939A1 (en) * | 2021-05-19 | 2022-11-24 | Acies Medical Llc | Point-of-use calibration system for iron ion detection system |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2861920A (en) * | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
| JPS5831210B2 (ja) * | 1973-04-09 | 1983-07-05 | 武田薬品工業株式会社 | アンテイナスイセイケンダクエキノセイゾウホウ |
| US4038389A (en) * | 1975-05-07 | 1977-07-26 | The Upjohn Company | Medroxyprogesterone acetate compositions |
| US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| JP2577744B2 (ja) | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
| ATE99943T1 (de) | 1989-12-06 | 1994-01-15 | Akzo Nv | Psychotropische wirkstoffe enthaltende stabilisierte loesungen. |
| US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
| JPH0597671A (ja) | 1991-10-04 | 1993-04-20 | Sumitomo Pharmaceut Co Ltd | 注射用凍結乾燥製剤 |
| CA2120197A1 (en) | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
| JP3862295B2 (ja) * | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| JP3543144B2 (ja) | 1995-03-11 | 2004-07-14 | 国際試薬株式会社 | 臨床検査用製剤 |
| US5780431A (en) | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
| JP2001501619A (ja) | 1996-10-04 | 2001-02-06 | アムジェン インコーポレーテッド | ｍｐｌリガンドを含有する医薬組成物 |
| US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
| US5880116A (en) * | 1996-12-13 | 1999-03-09 | Neurocal International | Use of celastrol to treat alzheimer's disease |
| JP3748970B2 (ja) | 1997-01-31 | 2006-02-22 | 電気化学工業株式会社 | ヒアルロン酸ナトリウム含有水溶液 |
| KR100508227B1 (ko) | 1997-03-14 | 2006-03-23 | 센주 세이야꾸 가부시키가이샤 | 로테프레드놀에타보네이트수성현탁액 |
| US6923956B1 (en) * | 1997-09-23 | 2005-08-02 | Rentschler Biotechnologie Gmbh | Liquid interferon-β formulations |
| US5968918A (en) * | 1997-10-17 | 1999-10-19 | Kanda; Iwao | Method for the prevention of coronary artery spasm |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| DE69913116T2 (de) | 1998-04-02 | 2004-06-03 | Akzo Nobel N.V. | Orale flüssige lösung enthaltend das antidepressivum mirtazapine |
| HU227347B1 (en) | 1999-10-04 | 2011-04-28 | Novartis Vaccines & Diagnostic | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
-
2000
- 2000-05-15 US US09/571,395 patent/US6495534B2/en not_active Expired - Lifetime
-
2001
- 2001-04-25 PL PL365793A patent/PL203075B1/pl unknown
- 2001-04-25 CN CNB018095895A patent/CN100473376C/zh not_active Expired - Lifetime
- 2001-04-25 IN IN1996CH2002 patent/IN224279B/en unknown
- 2001-04-25 CZ CZ20023750A patent/CZ303872B6/cs not_active IP Right Cessation
- 2001-04-25 NZ NZ522324A patent/NZ522324A/en not_active IP Right Cessation
- 2001-04-25 WO PCT/EP2001/004643 patent/WO2001087266A1/en active IP Right Grant
- 2001-04-25 DE DE60116084T patent/DE60116084T2/de not_active Expired - Lifetime
- 2001-04-25 SK SK1598-2002A patent/SK287641B6/sk not_active IP Right Cessation
- 2001-04-25 AT AT01945040T patent/ATE313316T1/de active
- 2001-04-25 MX MXPA02011195A patent/MXPA02011195A/es active IP Right Grant
- 2001-04-25 EA EA200201208A patent/EA007682B1/ru not_active IP Right Cessation
- 2001-04-25 HU HU0302021A patent/HU229800B1/hu unknown
- 2001-04-25 SI SI200130485T patent/SI1282402T1/sl unknown
- 2001-04-25 CA CA002409059A patent/CA2409059C/en not_active Expired - Lifetime
- 2001-04-25 AU AU2001267371A patent/AU2001267371B2/en not_active Expired
- 2001-04-25 BR BR0110841-7A patent/BR0110841A/pt not_active Application Discontinuation
- 2001-04-25 JP JP2001583735A patent/JP4205341B2/ja not_active Expired - Lifetime
- 2001-04-25 ES ES01945040T patent/ES2254443T3/es not_active Expired - Lifetime
- 2001-04-25 EP EP01945040A patent/EP1282402B1/en not_active Expired - Lifetime
- 2001-04-25 IL IL152537A patent/IL152537A/en active IP Right Grant
- 2001-04-25 KR KR1020027015431A patent/KR100828957B1/ko active IP Right Grant
- 2001-04-25 EE EEP200200631A patent/EE05376B1/xx unknown
- 2001-04-25 DK DK01945040T patent/DK1282402T3/da active
- 2001-04-25 AU AU6737101A patent/AU6737101A/xx active Pending
- 2001-05-09 TW TW090111029A patent/TWI256310B/zh not_active IP Right Cessation
- 2001-05-14 PE PE2001000431A patent/PE20011322A1/es active IP Right Grant
- 2001-05-14 AR ARP010102268A patent/AR029924A1/es not_active Application Discontinuation
-
2002
- 2002-08-21 US US10/225,320 patent/US20030114430A1/en not_active Abandoned
- 2002-10-10 US US10/267,690 patent/US20030130245A1/en not_active Abandoned
- 2002-10-29 ZA ZA200208738A patent/ZA200208738B/xx unknown
- 2002-11-13 NO NO20025431A patent/NO332215B1/no not_active IP Right Cessation
-
2003
- 2003-09-11 HK HK03106493.6A patent/HK1054194B/zh not_active IP Right Cessation
-
2004
- 2004-12-21 IL IL16588804A patent/IL165888A0/xx unknown
-
2014
- 2014-12-18 AR ARP140104760A patent/AR098830A2/es unknown
-
2018
- 2018-05-14 AR ARP180101264A patent/AR111695A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO332215B1 (no) | Stabiliserte vandige suspensjonsformulering for parenteral administrering, anvendelse av denne samt ampulle inneholdende formuleringen | |
| AU2001267371A1 (en) | Stabilized aqueous suspensions for parenteral use | |
| KR20090093581A (ko) | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 | |
| WO2018045091A1 (en) | Ophthalmic compositions | |
| JP7269992B2 (ja) | 医薬製剤 | |
| US11642355B2 (en) | Pharmaceutical compositions of testosterone | |
| US6025396A (en) | Stable prostaglandin E1-containing injectable composition | |
| JP6501399B2 (ja) | ペメトレキセドを含有する注射用溶液製剤 | |
| KR20200035047A (ko) | 클로르헥시딘을 함유하는 의약 조성물 | |
| US20030165568A1 (en) | Stabilized steroidal suspension | |
| WO2022034614A1 (en) | Phytonadione compositions | |
| JPWO2018003796A1 (ja) | 眼科用製品及び粘度低下抑制方法 | |
| KR20180085496A (ko) | 피페라실린 또는 그의 염 및 타조박탐 또는 그의 염을 포함하는 동결건조제제 | |
| JPH1149698A (ja) | 安定性を向上させたラクトフェリンの水性製剤 | |
| WO2018151143A1 (ja) | 製剤密封容器およびその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |